Clinical Trials in China / NCT06859515
Recruiting
Observational
A Long-term Follow up Study of EXG102-031 in Participants With wAMD
NCT06859515 · tracked via the Priya Life Science China tracker
Condition(s) studied
Wet Age-related Macular Degeneration
Investigational drug(s) / intervention(s)
No intervention, only for observational studies
No intervention, only for observational studies: No intervention, only for observational studies
Study summary
This is a long-term, safety and efficacy follow-up study of patients in the EXG102-031-111 gene therapy clinical trial for wAMD. Patients will complete visits from the parent study, and then into this long-term follow-up study for continuous safety monitoring for up to 5 years.
Eligibility
Inclusion Criteria:
1. Previously received treatment with EXG102-031 in the study (EXG102-031-111);
2. Paticipantes are informed consent and willingness to follow protocol procedures.
Exclusion Criteria:
1\. Paticipantes are unwilling or unable to participate in long-term follow-up
Primary outcome measure(s)
- long-term safety：the types, severity, and incidence of serious adverse events (SAEs), adverse events (AEs). — 4 years
the types, severity, and incidence of serious adverse events (SAEs), adverse events (AEs).
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Peking University People's Hospital | Beijing | China | Recruiting |
More Guangzhou Jiayin Biotech Ltd trials in China
Other trials for the same condition
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06859515 on ClinicalTrials.gov ↗ ← All trials in China